CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 29, 2018	Dec. 30, 2017
Cash Flows from Operating Activities:
Net income	$ 34,184	$ 33,692
Non-cash items:
Depreciation and amortization	79,637	66,267
Impairment of assets	21,170	218
Stock-based compensation expense	12,743	7,360
Gain on divestiture	0	(8,000)
Provision for losses on accounts receivable and inventory	3,220	514
Other non-cash operating activities	1,038	398
Change in operating assets and liabilities:
Change in accounts receivable	(19,752)	8,204
Change in inventories	(11,624)	17,460
Change in prepaid income taxes	(1)	805
Change in other assets and other liabilities	12,100	17,747
Change in accounts payable and accrued expenses	5,928	18,058
Net cash provided by operating activities	138,643	162,723
Cash Flows from Investing Activities:
Capital expenditures	(105,245)	(55,696)
Proceeds from divestiture	0	9,000
Proceeds from sale of property, plant and equipment	2,314	1,627
Net cash used in investing activities	(102,931)	(45,069)
Cash Flows from Financing Activities:
Term loan borrowings	347,780	0
Term loan borrowings	(258,103)	(45,054)
Proceeds from employee stock purchase plan	3,254	3,246
Proceeds from exercise of stock options	9,446	33,239
Share repurchases	(160,000)	0
Other financing activities	0	579
Net cash used in financing activities	(57,623)	(7,990)
Effect of exchange rates on cash and cash equivalents	(3,387)	2,363
Net Change in Cash and Cash Equivalents	(25,298)	112,027
Cash and Cash Equivalents at Beginning of Period	180,169	139,564
Cash and Cash Equivalents at End of Period	154,871	251,591
Supplemental Disclosures of Cash Flow Information:
Interest paid	9,492	5,684
Income taxes paid	6,233	7,320
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 12,100	$ 5,424